AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2017

Oct 10, 2017

32418_dirs_2017-10-10_fb3d4904-6f3a-490c-ac73-39690c20d606.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-10-05

Reporting Person: FARR KEVIN M (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-05	Stock Option (right to buy)	$4.24	A	1000000	Acquired	2027-10-04	Common Stock (1000000)	Direct

Footnotes

F1: The number of shares subject to the option shall vest in equal monthly installments over three years such that all the shares subject to the option shall have vested on the third anniversary of October 5, 2017.